Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ: ROIV )

12.00 +0.03 (+0.25%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
From Roivant Sciences
Via GlobeNewswire
5 Analysts Have This to Say About Roivant Sciences
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
Via Benzinga
Why Shares of Roivant Sciences Jumped This Week
The company's stock benefited from another company's buyout. 
Via The Motley Fool
Analyst Expectations for Roivant Sciences's Future
Via Benzinga
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission
Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old... 
Via Benzinga
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
Expert Ratings for Roivant Sciences
Via Benzinga
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so. 
Via The Motley Fool
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now
These two biopharma stocks could be poised for a major growth spurt. 
Via The Motley Fool
EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis
While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up. 
Via Benzinga
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today. 
Via The Motley Fool
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
Merck is branching into immune-mediated diseases with this takeover. 
Via Investor's Business Daily
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93... 
Via Benzinga
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
From Lokavant
Via Business Wire
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
From Lokavant
Via Business Wire
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
From Covant Therapeutics
Via GlobeNewswire
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. 
Via Benzinga
Why Shares of Roivant Sciences Were Down Tuesday
After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains. 
Via The Motley Fool
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
From Roivant Sciences
Via GlobeNewswire
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
PVTX-321 and PVTX-405 Achieve Development Candidate Nomination 
From Roivant Sciences
Via GlobeNewswire
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Announces Change to its Board of Directors
From Roivant Sciences
Via GlobeNewswire
Immunovant Could Potentially Be An M&A Target, Writes Analyst
Via Benzinga
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.